![]() |
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CARDIOVASCULAR
Oregon Hearing Research Center, Oregon Health and Science University, Portland, Oregon (Z.-G.J., X.-R.S., B.-C.G., H.Z., Y.-Q.Y.); and Department of Otolaryngology, Eye Ear Nose and Throat Hospital, Fudan University, Shanghai, People's Republic of China (H.Z.)
Acetylcholine (ACh) induces hyperpolarization and dilation in a variety of blood vessels, including the cochlear spiral modiolar artery (SMA) via the endothelium-derived hyperpolarization factor (EDHF). We demonstrated previously that the ACh-induced hyperpolarization in the SMA originated in the endothelial cells (ECs) by activating a Ca2+-activated K+ channel (KCa); the hyperpolarization in smooth muscle cells was mainly an electrotonic spread via gap junction coupling. In the present study, using intracellular recording, immunohistology, and vascular diameter tracking techniques on in vitro SMA preparations, we found that 1) ACh-induced hyperpolarization was suppressed by intermediate-conductance KCa (IK) blockers clotrimazole (IC50 = 116 nM) and nitrendipine and by the calmodulin antagonist trifluoperazine, but it was not suppressed by the big-conductance KCa blocker iberiotoxin. The immunoreactivity to anti-SK4/IK1 antibody was localized mainly in ECs. 2) The three dihydropyridinesnifedipine, nitrendipine, and nimodipineall concentration-dependently inhibited the ACh-induced hyperpolarization, with an IC50 value of 455, 34, and 3.2 nM, respectively. 3) Among other L-type Ca2+ channel (IL) blockers, 10 µM verapamil exerted a 20% inhibition on ACh-induced hyperpolarization, whereas diltiazem and the metal ion Ca2+ channel blockers Cd2+ and Ni2+ had no effect. 4) Nitrendipine and charybdotoxin abolished ACh-induced dilation in the SMA. We conclude that ACh-induced hyperpolarization in the SMA is generated mainly by activation of the IK in the ECs, and dihydropyridines suppress the EDHF-mediated hyperpolarization by blocking the IK channel, not the IL channel. The clinical relevance of this dihydropyridine action is discussed.
Address correspondence to: Dr. Zhi-Gen Jiang, Oregon Hearing Research Center, NRC04, Oregon Health and Science University, Portland, OR 97239. E-mail: jiangz{at}ohsu.edu
This article has been cited by other articles:
![]() |
K. A. Dora, N. T. Gallagher, A. McNeish, and C. J. Garland Modulation of Endothelial Cell KCa3.1 Channels During Endothelium-Derived Hyperpolarizing Factor Signaling in Mesenteric Resistance Arteries Circ. Res., May 23, 2008; 102(10): 1247 - 1255. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. D. Dietz, S. Du, C. W. Bolten, M. A. Payne, C. Xia, J. R. Blinn, J. W. Funder, and X. Hu A Number of Marketed Dihydropyridine Calcium Channel Blockers Have Mineralocorticoid Receptor Antagonist Activity Hypertension, March 1, 2008; 51(3): 742 - 748. [Abstract] [Full Text] [PDF] |
||||